Give a medicines opportunity a stronger path into practice.
A pharmaceutical proposition has to meet the organisations that will assess, purchase, supply or use it. Those organisations need more than a compelling introduction. They need to understand the evidence, practical requirements and reason to change their current approach.
NEUVIOR’s Medicines Intelligence work examines that space between a promising opportunity and useful implementation. PHARMORIS, the Medicines Action Layer, gives the programme a product focus. Our industry discussions begin with a defined medicines problem and the evidence needed to help responsible people make a better next decision.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
Find the barrier that matters to the receiving organisation.
A manufacturer may be developing a generic-medicines proposition. A supplier may be addressing recurring questions across customers. A growing pharmaceutical or technology business may need to understand where its idea meets operational or professional resistance.
The useful question is specific. Is the receiving team missing evidence, a local comparison, confidence in the delivery requirements or capacity to introduce the change? Identifying that barrier helps concentrate effort. It can also show that a different first setting, a narrower proposition or additional research would create a stronger route forward than a larger marketing claim.
Bring the right functions into the case.
Medical affairs, market access, regulatory, quality, supply and commercial teams contribute different knowledge. A decision about evaluating medicines intelligence may be sponsored by one of those functions and authorised by a business-unit budget holder or another delegated buyer.
The scope needs to establish who owns the problem, who can provide appropriate information and which reviewers must be involved. Contracting, medical and legal colleagues may shape what can be examined and shared. For an SME, one person may carry several roles; for a larger business, they may sit across teams. A useful briefing makes that decision process clear enough to move the work.
Understand the buyer beyond your own business.
A provider medicines team needs to judge appropriateness and practical delivery. A pharmacy owner needs an approach that fits its staff and service economics. A health-system buyer needs a defensible account of resources, oversight and the work carried by its organisation.
Those incentives should shape the proposition early. NHS medicines-optimisation guidance in England emphasises collaborative delivery across clinical, financial and organisational responsibilities. A useful industry case respects the receiving organisation’s priorities and decision authority. It distinguishes the evidence a sponsor brings from the professional judgement that belongs to the people assessing the proposed change. This creates a clearer basis for an honest, productive conversation.
Work through one generic-medicines example.
Consider a manufacturer examining why a generic-medicines opportunity is difficult to progress in a defined provider setting. The question could involve the evidence the receiving team needs, a supply condition, an implementation requirement or the resources required to introduce a change.
A proposed evaluation could organise those questions into a reviewable case, compare the existing approach and identify what additional information would alter the decision. Qualified participants would examine relevance, source quality, assumptions and professional effort. The useful output is a clearer next step for the organisations involved. This illustrative case does not presume adoption, a regulatory submission service or access to a provider’s confidential decisions.
Make the economics of the next step explicit.
An assessment should explain why the work is worth commissioning. Which uncertainty will it reduce? Who can act on the finding? What would a favourable result justify, and what would lead the business to change direction?
Include the cost of gathering appropriate evidence, participating in review and introducing a different approach. A supplier’s commercial opportunity and a healthcare organisation’s benefit are related questions, with different definitions and responsibilities. A strong case keeps both understandable. This helps a business decide whether to commission a focused evaluation, invest in further development or concentrate resources on a proposition with a clearer buyer and use.
Build evidence that strengthens the commercial conversation.
Our planned PHARMORIS evaluation themes include review quality, appropriate trust, implementation follow-through and the full economics of use. The comparison begins with competent existing practice and includes the checking and support introduced by the new approach.
Industry can contribute a concrete problem, relevant professional expertise or an authorised operational perspective. Research and evaluation specialists can help design a revealing comparison. The result should clarify where the approach is useful and what further evidence is needed. Named participation, findings and commercial terms must be agreed before publication, so that a useful study does not become an unsupported claim about another organisation.
Bring a proposition with a decision behind it.
We welcome pharmaceutical businesses, suppliers, manufacturers, technology SMEs and professional teams with a medicines implementation question. Tell us the setting, the obstacle and the decision a better evidence case would support.
A PHARMORIS briefing can examine fit, the responsible buyer, appropriate contributors and the scope of a possible evaluation. The objective is a bounded piece of work with a clear commercial purpose and a finding that helps the next decision move forward.
Continue the programme
- When quality becomes a capital decision
A proposed manufacturing-quality evaluation linking operational uncertainty, investment options and measurable decision evidence.
- Which supply exception deserves attention first?
Explore a proposed wholesale exception-review evaluation that compares effort, escalation and operational consequences.
- Before a shortage becomes everybody’s problem
A proposed readiness review for marketing authorisation holders connecting supply evidence, reporting ownership and action.
- A forecast needs a reason to be believed
Explore demand uncertainty, stock movement and the evidence needed before a pharmaceutical supply decision changes.
- The lowest price is only one part of the tender
A proposed medicines tender evaluation comparing price, capacity, delivery conditions and supply resilience.
- When the temperature moves, the evidence must keep up
A proposed cold-chain evidence-preparation review for accountable medicines quality teams.
- A recall message is only useful when the action is clear
Explore a proposed recall-readiness exercise focused on product identity, communication, ownership and evidence of completion.
- Give the unanswered question a useful shape
A proposed medical-affairs evidence-gap review connecting stakeholder questions, available evidence and study decisions.
- Access is a decision. Adoption is a journey.
Explore a proposed industry review of local medicines implementation, capacity assumptions and evidence for market-access decisions.
- Can the available data answer the question?
A proposed feasibility review for industry real-world evidence studies, with a clear question, comparator and data-fit decision.
- Public medicines data. A sharper commercial question.
Explore how public medicines datasets could support bounded business decisions without overstating market size, prices or access.
- Governed AI begins with a decision about its role
A proposed AI-use evaluation for medicines organisations defining context, responsibility, evidence and limits before adoption.
- A convincing summary is not enough
A proposed evaluation of AI-assisted medicines evidence preparation using source accuracy, omissions and reviewer effort.
- From a changed document to a clear next question
A proposed regulatory-intelligence triage review connecting official changes, product relevance and accountable assessment.
- Before a product leaves the portfolio
A proposed discontinuation decision review connecting commercial constraints, supply implications, reporting and alternatives.
- Traceability has to work when something does not match
A proposed US medicines traceability exception-review study for manufacturers, distributors and dispensers.
- The handoff is part of the manufacturing decision
A proposed contract-manufacturing decision review connecting responsibilities, assumptions and implementation evidence.
- Supply is back. What should change next time?
A proposed post-shortage review distinguishing supply recovery, residual workload and lessons for accountable improvement.